CL2018001548A1 - Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas - Google Patents

Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas

Info

Publication number
CL2018001548A1
CL2018001548A1 CL2018001548A CL2018001548A CL2018001548A1 CL 2018001548 A1 CL2018001548 A1 CL 2018001548A1 CL 2018001548 A CL2018001548 A CL 2018001548A CL 2018001548 A CL2018001548 A CL 2018001548A CL 2018001548 A1 CL2018001548 A1 CL 2018001548A1
Authority
CL
Chile
Prior art keywords
treatment
liver diseases
subject
intrahepatic cholestasis
related liver
Prior art date
Application number
CL2018001548A
Other languages
English (en)
Spanish (es)
Inventor
Bo Möllstam
Fredrik Karlsson
Original Assignee
Metabogen Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabogen Ab filed Critical Metabogen Ab
Publication of CL2018001548A1 publication Critical patent/CL2018001548A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733Fructosans, e.g. inulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CL2018001548A 2015-12-14 2018-06-11 Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas CL2018001548A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562266771P 2015-12-14 2015-12-14

Publications (1)

Publication Number Publication Date
CL2018001548A1 true CL2018001548A1 (es) 2018-07-20

Family

ID=57570064

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001548A CL2018001548A1 (es) 2015-12-14 2018-06-11 Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas

Country Status (16)

Country Link
US (1) US20180369297A1 (https=)
EP (1) EP3389680B1 (https=)
JP (2) JP2018537484A (https=)
KR (1) KR20180094950A (https=)
CN (1) CN109069548A (https=)
AU (1) AU2016374365B2 (https=)
BR (1) BR112018012022A2 (https=)
CA (1) CA3008195A1 (https=)
CL (1) CL2018001548A1 (https=)
ES (1) ES2962302T3 (https=)
IL (1) IL259480B2 (https=)
MX (1) MX2018007227A (https=)
RU (1) RU2743405C2 (https=)
SG (1) SG11201804255QA (https=)
WO (1) WO2017102816A1 (https=)
ZA (1) ZA201804660B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA3212215A1 (en) 2012-11-23 2014-05-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3668527A1 (en) * 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
EP3870691A4 (en) 2018-09-13 2022-09-07 Xbiome Inc. METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL AND INFLAMMATORY DISORDERS
CN112280720B (zh) * 2020-11-19 2021-07-13 山东龙昌动物保健品有限公司 一株多形拟杆菌gl-02及其与胆汁酸复配的复合菌剂与应用
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
GB2628547A (en) * 2023-03-27 2024-10-02 Univ Newcastle Probiotic and postbiotic compositions, products and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
WO2000071138A2 (en) * 1999-05-25 2000-11-30 Gregor Reid Oral administration of lactobacillus for the maintenance of health in women
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
CA2642431A1 (en) * 2006-02-15 2007-08-23 Nestec S.A. Use of bifidobacterium longum for the prevention and treatment of inflammation
US20120128633A1 (en) * 2009-04-30 2012-05-24 Campagnie Gervaise Donone Use of collinsella aerofaciens for reducing bloating
CN102539791A (zh) * 2012-01-09 2012-07-04 宁波天康生物科技有限公司 总胆汁酸的定量测定及测定试剂盒
AU2014331610B2 (en) * 2013-10-03 2019-11-07 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof

Also Published As

Publication number Publication date
RU2018124487A (ru) 2020-01-10
EP3389680C0 (en) 2023-10-11
EP3389680A1 (en) 2018-10-24
SG11201804255QA (en) 2018-06-28
IL259480B2 (en) 2023-09-01
JP2022166039A (ja) 2022-11-01
WO2017102816A1 (en) 2017-06-22
ZA201804660B (en) 2022-12-21
CN109069548A (zh) 2018-12-21
BR112018012022A2 (pt) 2018-12-04
RU2018124487A3 (https=) 2020-05-29
JP2018537484A (ja) 2018-12-20
RU2743405C2 (ru) 2021-02-18
IL259480B1 (en) 2023-05-01
CA3008195A1 (en) 2017-06-22
US20180369297A1 (en) 2018-12-27
AU2016374365A1 (en) 2018-07-12
AU2016374365B2 (en) 2023-04-13
MX2018007227A (es) 2018-08-01
ES2962302T3 (es) 2024-03-18
KR20180094950A (ko) 2018-08-24
EP3389680B1 (en) 2023-10-11
IL259480A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CL2018001548A1 (es) Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas
ECSP21001547A (es) Formulación farmacéutica de odevixibat
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
PH12019501323A1 (en) Compositions comprising sulfated polysaccharides
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
GEP20217328B (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX381283B (es) Tratamiento de pénfigo.
PE20170904A1 (es) Esteroides neuroactivos, composiciones y usos de los mismos
AR101740A1 (es) Terapia de combinación y composiciones
EA201890859A1 (ru) Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
MX2018004132A (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
MX2019007161A (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
BR112017018758A2 (pt) alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide
BR112019006880A2 (pt) compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
EA201990560A1 (ru) Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии
BR112017014016A2 (pt) método de redução da pressão intraocular, e, composição farmacêutica.